Cargando…
High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea
BACKGROUND: Persistence of Ebola virus (EBOV) in semen remains of deep concern, as sexual transmission of EBOV seems plausible up to 6 months after acute phase of Ebola virus disease (EVD). Favipiravir, a broad spectrum antiviral product, has been evaluated in reducing EVD mortality in Guinea in 201...
Autores principales: | Eloy, Philippine, Laouénan, Cédric, Beavogui, Abdoul Habib, Keita, Sakoba, Manchon, Pauline, Etard, Jean-François, Sissoko, Daouda, Mentré, France, Malvy, Denis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808076/ https://www.ncbi.nlm.nih.gov/pubmed/35127447 http://dx.doi.org/10.1016/j.idcr.2022.e01412 |
Ejemplares similares
-
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017) -
Ebola outbreak in Guinea, 2021: Clinical care of patients with Ebola virus disease
por: Pare, Boyo C., et al.
Publicado: (2023) -
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study
por: Kerber, Romy, et al.
Publicado: (2019) -
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
por: Sissoko, Daouda, et al.
Publicado: (2016) -
Is Guinea meeting the challenges to control the new ebola virus disease outbreak in West Africa?
por: Delamou, Alexandre, et al.
Publicado: (2021)